A number of novel treatment strategies for multiple myeloma (MM) are being studied. A few such studies are discussed here by Noopur Raje, MD, of Massachusetts General Hospital Cancer Center, Boston, MA. Prof. Raje covers the use of venetoclax in combination with carfilzomib for relapsed/refractory MM (NCT02899052). She also mentions the combination of low-dose lenalidomide with the JAK inhibitor ruxolitinib (NCT03110822). This video was recorded at the American Society of Oncology (ASCO) 2018 Annual Meeting in Chicago, IL.
Venetoclax and ruxolitinib treatment strategies for myeloma
